- J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketJohnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The dru…Endpoints · 2mo ago↗ source
- Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit→ Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of the Boehringer Cares Foundation. Peer Review informed you about her…Endpoints · 2mo ago↗ source
- Two biotechs raise a combined $556M in latest spurt of IPOs<figure><div><img src="https://imgproxy.divecdn.com/Ll8Kl4Xj3nHdTKBGSRbP6tU2Gjn-xo-ocHpjXqrNGQQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDAxNzQ1Njc1LmpwZ…